A clinical trial investigating biodistribution and shedding of an oncolytic virus

Affiliations

¹ Department of Molecular Medicine, University of Padua, Italy.
² Department of Molecular Medicine, University of Padua, Italy. Electronic address: giorgio.palu@unipd.it.

Comment

Alberto Reale et al. EBioMedicine. 2019 Sep.

. 2019 Sep:47:4-5.

doi: 10.1016/j.ebiom.2019.08.011. Epub 2019 Aug 13.

¹ Department of Molecular Medicine, University of Padua, Italy.
² Department of Molecular Medicine, University of Padua, Italy. Electronic address: giorgio.palu@unipd.it.

No abstract available

Comment on

Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma.
Andtbacka RHI, Amatruda T, Nemunaitis J, Zager JS, Walker J, Chesney JA, Liu K, Hsu CP, Pickett CA, Mehnert JM. Andtbacka RHI, et al. EBioMedicine. 2019 Sep;47:89-97. doi: 10.1016/j.ebiom.2019.07.066. Epub 2019 Aug 10. EBioMedicine. 2019. PMID: 31409575 Free PMC article. Clinical Trial.

1. Russell S.J., Peng K.W., Bell J.C. Oncolytic virotherapy. Nat Biotechnol. 2012;30(7) - PMC - PubMed
1. Conry R.M., Westbrook B., McKee S., Norwood T.G. Talimogene laherparepvec: first in class oncolytic virotherapy. Hum Vaccin Immunother. 2018;14(4):839–846. - PMC - PubMed
1. Liu B.L., Robinson M., Han Z.Q. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003;10(4) - PubMed
1. Franke V., Berger D.M., Klop W.M. High response rates for T-VEC in early metastatic melanoma (stage IIIB/C-IVM1a) Int J Cancer. 2019;145:974–978. - PubMed
1. Gangi A., Zager J.S. Expert Opin Drug Saf. 2017;16(2):265–269. - PubMed